GSK Stock Recent News

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM.

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, have not worked. This makes Nucala the first anti-interleukin-5 treatment available for this condition in China, where an estimated 30 million people live with CRSwNP.

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.

Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.